Voyage: US only, 52-week study looking at MM120 versus Placebo
Is anxiety disrupting your daily life?
Learn about a study researching a potential investigational treatment for generalized anxiety disorder (GAD).
Learn moreWhat is MM120?
MM120 is a potential investigational treatment option in development that may improve your anxiety symptoms. This investigational treatment option is a pharmaceutically optimized form of lysergide-D-tartrate, a psychedelic more commonly known as LSD.
Our Studies
Panorama: Global, 52-week study looking at MM120 versus Placebo
Major Eligibility Criteria
Site staff will assess the full list of eligibility criteria
Inclusion Criteria
1
Diagnosis of GAD Per DSM-5
The DSM-5 is the widely accepted guide for classifying and diagnosing mental health illnesses
2
Male or Female Aged 18 to 74
3
HAM-A Total Score ≥20
HAM-A is an evaluation administered by a clinician that helps assess the severity of anxiety symptoms in an individual
Exclusion Criteria
1
Certain psychiatric disorders (other than GAD)
2
First degree relative (such as your parent or a sibling) with or lifetime history of a psychotic disorder or bipolar disorder
3
Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
4
Any clinically significant unstable illness
Find Your Nearest Site Section
Click on the map below to see study site locations near you and their contact information.
